Department of Child Neurology and Psychiatry, IRCCS Mondino Foundation (Member of ERN-Epicare), Pavia, Italy.
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Orphanet J Rare Dis. 2023 Mar 21;18(1):63. doi: 10.1186/s13023-023-02628-2.
GLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases.
To describe the implementation of a national web-based registry for GLUT1-DS.
This is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient's sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient's demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies.
Five Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments.
We describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.
GLUT1 缺乏综合征是一种罕见的遗传性神经障碍,生酮饮食治疗是其金标准和终身治疗方法。患者登记处是提供罕见病见解和真实世界数据的有力工具。
描述一个用于 GLUT1-DS 的全国性网络登记处的实施情况。
这是一个回顾性和前瞻性的、多中心的、观察性的登记处,是与意大利 GLUT1-DS 协会合作开发的,基于创新、灵活和可配置的云计算技术平台,根据管理患者敏感数据的最严格要求进行结构化。Glut1 登记处收集患者人口统计学、病史、症状、基因型、临床和仪器评估以及治疗的基线和随访数据。
意大利的 5 个中心加入了该登记处,还有另外 2 个中心正在加入。在运行的头两年,已经收集了 67 名患者(40 名女性和 27 名男性)的数据。大多数患者(60%)的发病年龄在 1 岁以内,几乎一半的病例(51%)在婴儿期确诊。发病时的症状主要是阵发性的(大多是癫痫发作和阵发性眼球运动障碍)或阵发性和固定症状混合的(大多是精神运动发育迟缓)。目前,大多数患者(79%)正在接受生酮饮食治疗。
我们描述了基于网络的全国性 GLUT1-DS 登记处的设计、开发和部署背后的原则。它代表了从发病到成年期更全面了解疾病的一个里程碑。从技术、法律和组织的角度来看,它也是一个良性模式,因此可能成为其他罕见病登记处实施的典范。